News | September 10, 2024
Briefs: Wanbury and Bafna Pharmaceuticals
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
The recent inspection covered both cGMP and PAI processes
The patient has been isolated in a designated hospital and is currently stable
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
Konieczny has served as Interim CEO since April 2024
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Subscribe To Our Newsletter & Stay Updated
